Oncolytics Biotech Inc. (ONCY) Earnings History
Net Loss27 years of earnings data (1999–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Oncolytics Biotech Inc. (ONCY) Earnings Overview
As of June 28, 2026, Oncolytics Biotech Inc. (ONCY) reported trailing twelve-month net income of -$35M, reflecting +0.0% year-over-year growth. The company earned $-0.31 per diluted share over the past four quarters.
Looking at the long-term picture, ONCY's historical earnings data spans multiple years. The company achieved its highest annual net income of -$574,462 in fiscal 1999.
Oncolytics Biotech Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$506M net income), CLDX (-$284M net income, -17253.3% margin), NKTR (-$158M net income, -297.1% margin), ONCY has comparable earnings metrics. Compare ONCY vs IMVT →
ONCY Earnings vs Peers
Earnings metrics vs comparable public companies
ONCY Historical Earnings Data (1999–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$39M | -24.4% | -$39M | $-0.41 | - | - |
| 2024 | -$32M | -54.2% | -$35M | $-0.41 | - | - |
| 2023 | -$21M | -7.8% | -$25M | $-0.41 | - | - |
| 2022 | -$19M | +9.1% | -$21M | $-0.43 | - | - |
| 2021 | -$21M | -25.0% | -$21M | $-0.49 | - | - |
| 2020 | -$17M | +63.2% | -$19M | $-0.48 | - | - |
| 2019 | -$46M | -167.4% | -$21M | $-2.06 | - | - |
| 2018 | -$17M | -9.1% | -$17M | $-1.06 | - | - |
| 2017 | -$16M | -3.1% | -$16M | $-1.12 | - | - |
| 2016 | -$15M | -10.3% | -$15M | $-1.20 | - | - |
| 2015 | -$14M | +26.3% | -$14M | $-1.16 | - | - |
| 2014 | -$19M | +20.9% | -$19M | $-2.01 | - | - |
| 2013 | -$24M | +35.3% | -$24M | $-2.68 | - | - |
| 2012 | -$36M | -25.2% | -$37M | $-4.54 | -749.7% | -756.2% |
| 2011 | -$29M | -45.4% | -$29M | $-3.89 | - | - |
| 2010 | -$20M | -17.5% | -$20M | $-3.04 | - | - |
| 2009 | -$17M | +3.2% | -$17M | $-3.27 | - | - |
| 2008 | -$18M | -12.2% | -$18M | $-4.03 | - | - |
| 2007 | -$16M | -9.4% | -$17M | $-3.68 | - | - |
| 2006 | -$14M | -11.9% | -$15M | $-3.74 | - | - |
| 2005 | -$13M | +1.3% | -$13M | $-3.71 | -1631.5% | -1599.4% |
| 2004 | -$13M | -51.6% | -$13M | $-4.31 | -1851.5% | -1805.2% |
| 2003 | -$9M | -40.3% | -$7M | $-3.48 | -2727.1% | -2112.4% |
| 2002 | -$6M | +1.3% | -$7M | $-2.74 | -2916.4% | -3232.4% |
| 2001 | -$6M | -70.8% | -$7M | $-3.17 | - | - |
| 2000 | -$4M | -529.0% | -$5M | $-1.98 | -1165.5% | -1498.6% |
| 1999 | $-574,462 | - | $-577,370 | $-0.01 | - | - |
Download Data
Export ONCY earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ONCY — Frequently Asked Questions
Quick answers to the most common questions about buying ONCY stock.
What is ONCY earnings per share (EPS)?
ONCY trailing twelve-month (TTM) diluted EPS is $-0.31, reflecting +0.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1999 to 2025 is available in the table on this page.
What is Oncolytics Biotech Inc.'s net income?
Oncolytics Biotech Inc. (ONCY) trailing twelve-month net income is $-35M as of 2025. Earnings declined +0.0% year-over-year.
Is ONCY profitable?
ONCY is not currently profitable on a TTM basis, reporting a net loss of $-35M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ONCY's earnings growth rate?
ONCY compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1999 to 2025.
What are ONCY's profit margins?
Oncolytics Biotech Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -10245.9%.
Is ONCY growing earnings?
ONCY TTM EPS: $-0.31. Net income: $-35M. YoY earnings change: +0.0%.
What was ONCY's best earnings year?
Oncolytics Biotech Inc.'s highest annual net income on record is $-574462.00, achieved in fiscal year 1999. Earnings history on this page spans 1999 to 2025 and includes all annual and quarterly figures.
What were ONCY's earnings last quarter?
ONCY's most recent reported quarter was Q1 2026. Net income was $-13M with diluted EPS of $-0.11. For a full breakdown of all quarters, see the quarterly earnings table on this page.